Wednesday, October 21, 2020
News
NEWS HOME
»
PRESS RELEASES

Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries
  SocialTwist Tell-a-Friend  
   


Date: 29-04-2020 10:41AM
Source: Neuraptive Therapeutics, Inc.
Category: General, Science & Research, Healthcare & Biotechnology, Medical Devices, Pharmaceutical
Location: Philadelphia, United States

Business Wire India

  • NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves
  • Neuraptive will conduct a Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Patients with Acute Single Transected Peripheral Nerve Injuries of the Upper Extremities


Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs in the treatment of peripheral nerve injuries (PNI), today announced that the U.S. Food and Drug Administration (FDA) has cleared Neuraptive's Investigational New Drug (IND) application for NTX-001 in patients with acute single transected PNI.

"We are pleased to have received clearance for the company’s first IND, and are excited to initiate the trial later this year," said Evan Tzanis, Executive Vice President and Head of Research and Development. "We look forward to working with investigators as we advance Neuraptive’s NTX-001 into the clinic for the treatment of peripheral nerve injuries."

Peripheral nerve injuries resulting in surgeries are common, occurring in more than 600,000 patients annually in the United States, with approximately 80% of nerve injuries occur in the upper extremities. Neuraptive’s Phase 2 study will evaluate the safety and efficacy of NTX-001 versus the current standard of care in upper extremity injuries. NTX-001 is being developed in the U.S. via the FDA 505 (b) (2) development pathway, in which the components contained in the product are present in existing, approved drug products, allowing for the potential of a more streamlined development program.

"Current interventions do not prevent the irreversible degeneration that occurs within 48 to 72 hours following injury. We believe that NTX-001 has the potential to diminish or prevent this degenerative process so that nerves recover more quickly, and patients can avoid disabilities that commonly result from these types of nerve injuries," said Ivan Gergel, MD, Executive Chairman of the Board of Neuraptive. "We are hopeful that NTX-001 can be a revolutionary treatment for physicians to offer their patients undergoing PNI repairs."

About Neuraptive Therapeutics

Neuraptive is creating innovative novel therapies for nerve repairs to improve clinical outcomes for patients and surgeons who care for them. The company's franchise therapeutic product, NTX-001, has the potential to improve the quality and speed of recovery of nerve sensation and function for eligible patients who have sustained traumatic injuries or who are undergoing reconstructive surgical procedures. Neuraptive is rapidly advancing its pipeline and will leverage its capabilities to transition into a clinical-stage company. Investors include New Rhein Healthcare Investors through its Fund 18 and Ben Franklin Technology Partners. The company is headquartered in Philadelphia, PA, and has offices near Boulder, CO, as well as surgical translational medical facilities at the Colorado University Anschutz Medical Center in Aurora, CO. For more information, see www.neuraptive.com.

About New Rhein Healthcare Investors

New Rhein is a venture capital/early growth stage fund manager whose investment strategy focuses on proven molecules used in new ways, such as new delivery forms and potential new uses and indications. In this way, New Rhein limits science-based risk and concentrates on development and execution. Prior investments have included medicines for Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics. New Rhein’s partners, associates, and advisors are knowledgeable former industry executives with solid track records of operational, investment, and transactional experience. New Rhein combines significant deal-making expertise with deep operating experience, allowing it to tailor the right deal for the right situation and work with its portfolio companies to achieve maximum value for their products. For more information, see www.newrhein.com.

Cautionary Note on Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. including, among others, statements we make regarding the time for the commencement of clinical trials. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.



CONTACTS :

Investor Relations Neuraptive Therapeutics, Inc
IR@neuraptive.com

Evan Tzanis
Phone: +1-484-787-3203

More Press Releases

HONOR, Red Bull Basement Collaborate to Accelerate Student Innovators in India

NetApp Brings the Simplicity and Flexibility of the Cloud to the Data Center with Updated Software Data Services

Velodyne Lidar Calls for Action to Improve Pedestrian Safety

JICA Supports India for Capacity Development on Railway Safety

Prevailion Named a 2020 Gartner “Cool Vendor” in Security Operations and Threat Intelligence Field

Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

IRIS Software Group acquires school management system, iSAMS

JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland

Alibaba Group Unveils Plans for 2020 11.11 Global Shopping Festival

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients

Entrust Launches Next-Generation, Secure Cloud-Based Direct-to-Card ID Desktop Issuance Solution

ITC Institutes DivX LLC’s Complaint Against Samsung, LG, TCL, MediaTek and Realtek

Ontario Teachers' Leads US$360M Investment Round Into Princeton Digital Group, Asia's Leading Data Centre Company

Global Processing Services Continues International Growth with Visa Investment

Cube Highways Closes on 30-year Concession of Nine Operating Roads With $684 Million Payment

uAvionix Files FAA TSO Application for World's First Certified Drone Transponder

Kasturba Medical College, India Wins XV Fujio Cup Quiz in NCRM NICHE 2020

Farasis and TOGG Signed a Letter of Intent to Develop Energy Storage Solutions for Turkey and Surrounding Countries

Datasite Enters Agreement to be Acquired by CapVest

Heilind Asia Pacific Wins the “Distribution and Service Excellence Award 2020”

Hong Kong Tourism Board Launches a Standardised Hygiene Protocol to Assure Visitors of a Safe and Healthy Stay

Activist Malala Yousafzai and American Football Coach Katie Sowers Among Others to Headline PMI® Virtual Experience Series

B2Broker Launches New Website and Branding as Part of Corporate Development and Expansion Plans

Bentley Systems announces Executive Appointments of Nicholas Cumins (Chief Product Officer), Katriona Lord-Levins (Chief Success Officer), and Chris Bradshaw (Chief Marketing Officer)

Uniphore Adds Robotic Process Automation Technology to its Arsenal to Accelerate Innovation in Contact Centers Around the World

Uniphore and NTT DATA Sign Multi-year Deal to Bring Conversational Service Automation to Contact Centers

AIM Releases Data Science Education Ranking 2020 for Online Courses in India

Alibaba Acquires Controlling Stake in Sun Art

Sachet Loans - The 2.0 Version of Personal Loans

Raysut Maldives Cement JV Formed; Acquisition of LafargeHolcim Stake Completed

Toshiba Launches 1200V Silicon Carbide MOSFET That Contributes to High-efficiency Power Supply

Shell Deepwater Selects Bentley's iTwin Platform for Project Delivery

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
CM should assure Punjab government will ...
Dharmendra Pradhan launches trial run of...
AYUSH Ministry reviews interventions tow...
FIR against BJP's Bisahu Lal Sahu for re...
Indian exports to US, China on rise in 2...
Man runs foundation to hand over unident...
More...    
 
 Top Stories
Rashami Desai turns 'Bangali girl' ... 
Haryana monsoon session to resume o... 
RJD slams Nitish on Bihar's backwar... 
Amit Sadh trains hard for 'Zidd' in... 
US govt files antitrust lawsuit aga... 
Sidharth Malhotra reports back to d... 
Pakistan's fate at FATF hangs in th... 
31 in fray for Nov 3 twin bypolls i...